Our Pricing

Maintenance Dose Wegovy Weight Loss - GPhC Regulated UK

Published on: June 03, 2026

Many UK patients wonder whether maintenance dose wegovy weight loss uk treatment continues to deliver results after reaching the 2.4mg dose. Clinical evidence from the STEP trials demonstrates that patients maintain significant weight reduction during the maintenance phase, with some experiencing continued gradual loss beyond the initial titration period [1]. At Cured Pharmacy, our UK prescribers support patients through every phase of semaglutide treatment, from initial dosing through long-term maintenance.

What Happens During Wegovy Maintenance Dose

The Wegovy maintenance dose is 2.4mg administered once weekly via subcutaneous injection [1]. You reach this dose after a 16-week titration schedule that gradually increases from 0.25mg to minimise gastrointestinal side effects whilst your body adapts to semaglutide.

Once you've reached 2.4mg, this becomes your ongoing maintenance dose for as long as treatment continues and remains clinically appropriate. The maintenance phase isn't simply about holding steady — clinical data shows that many patients continue to lose weight during this period, albeit typically at a slower rate than during initial titration [1][2].

In the STEP 1 trial, participants maintained on 2.4mg semaglutide achieved an average 14.9% body weight reduction over 68 weeks, with weight loss plateauing around week 60 before stabilising [1]. This demonstrates that the maintenance dose remains pharmacologically active in suppressing appetite and regulating blood glucose long after the titration phase ends.

Do You Continue Losing Weight on Wegovy Maintenance Dose

The short answer is yes, though individual responses vary considerably based on adherence, lifestyle factors, and metabolic differences. Clinical trial data shows that most participants continued experiencing weight reduction throughout the maintenance phase, though the rate of loss typically slows after the first 6-9 months [1][2].

In STEP 1, participants on the 2.4mg maintenance dose showed progressive weight loss until approximately week 60, after which weight stabilised rather than rebounding [1]. This pattern suggests that Wegovy's maintenance dose is sufficient to preserve the metabolic and appetite-suppressing effects that drive initial weight loss.

However, it's crucial to understand that semaglutide works most effectively when combined with reduced-calorie nutrition and increased physical activity. The medication enhances satiety and reduces food cravings, but sustained weight loss during maintenance requires ongoing behavioural modifications [3]. Our superintendent pharmacist Tarun Kumar regularly advises patients that the maintenance dose provides the physiological support, whilst lifestyle changes determine long-term success.

Factors Affecting Maintenance Phase Results

Several variables influence whether you continue losing weight during Wegovy maintenance. Metabolic adaptation — where your body adjusts to lower caloric intake by reducing energy expenditure — can slow progress even with consistent medication adherence [3]. Patients who maintain higher activity levels and avoid reverting to pre-treatment eating patterns typically see better sustained results.

Additionally, some patients reach a natural plateau where their body composition stabilises at a healthier weight. This isn't treatment failure — it represents a new equilibrium where the medication helps maintain weight loss rather than driving continuous reduction. Your UK prescriber will monitor your progress and adjust treatment recommendations accordingly.

Wegovy Maintenance Dose Clinical Evidence

The STEP clinical trial programme provides robust evidence for Wegovy's effectiveness during long-term maintenance. STEP 1 enrolled 1,961 adults with obesity or overweight plus weight-related comorbidities, randomising them to either 2.4mg semaglutide or placebo for 68 weeks [1].

Participants on the maintenance dose achieved an average 14.9% body weight reduction compared to 2.4% with placebo — a highly significant difference that persisted throughout the study period [1]. Importantly, weight loss continued beyond week 20 (when participants reached the 2.4mg dose), with the curve flattening rather than reversing around week 60.

STEP 4 examined what happens when patients discontinue Wegovy after reaching maintenance dose. Participants who stopped treatment regained approximately two-thirds of their lost weight within 48 weeks, whilst those continuing on 2.4mg maintained their weight loss [2]. This demonstrates that the maintenance dose provides ongoing pharmacological benefit rather than simply preserving earlier gains through residual effects.

How Wegovy Maintenance Dose Compares to Alternatives

Wegovy's 2.4mg maintenance dose represents the highest licensed semaglutide dose for weight management in the UK, approved by the MHRA following comprehensive clinical trials. Other GLP-1 receptor agonists use different dosing strategies and achieve varying results during long-term treatment.

Saxenda (liraglutide) requires daily injections at a 3mg maintenance dose, whilst Wegovy's once-weekly administration offers greater convenience for many patients. Clinical comparisons suggest semaglutide produces superior weight loss outcomes, though individual responses vary [4].

Newer dual-pathway treatments targeting both GLP-1 and GIP receptors have shown even greater weight reduction in clinical trials, though these remain subject to NHS England eligibility criteria and prescriber assessment. At Cured Pharmacy, we stock genuine UK-licensed weight management treatments at competitive pricing, with transparent costs displayed before your free consultation begins.

Choosing Between Weight Loss Medications

Your UK prescriber will consider multiple factors when recommending a specific treatment and maintenance dose, including your BMI, weight-related comorbidities, previous weight loss attempts, and tolerance of gastrointestinal side effects. Wegovy's maintenance dose suits patients who can commit to weekly injections and meet the MHRA-approved eligibility criteria.

All prescription weight loss medications available through Cured Pharmacy require clinical assessment by a UK-registered prescriber. Our online consultation takes under 3 minutes and ensures treatment safety whilst maintaining full regulatory compliance with GPhC standards.

Managing Side Effects During Wegovy Maintenance

Most patients find that gastrointestinal side effects — nausea, diarrhoea, constipation, and abdominal discomfort — diminish significantly once they've adapted to the 2.4mg maintenance dose [1]. The gradual titration schedule exists specifically to improve tolerability by allowing your digestive system to adjust incrementally.

However, some patients experience persistent nausea or other side effects even during maintenance. Practical strategies include eating smaller portions, avoiding high-fat meals, staying well-hydrated, and timing your injection consistently each week. If side effects remain troublesome, your prescriber may recommend temporarily reducing the dose before re-attempting 2.4mg.

Rare but serious adverse effects include pancreatitis, gallbladder problems, and hypoglycaemia (particularly in patients taking other glucose-lowering medications). Contact your prescriber immediately if you experience severe abdominal pain, persistent vomiting, or signs of low blood sugar during maintenance treatment [1]. Our clinical team at Cured Pharmacy remains available throughout your treatment journey to address concerns and adjust your care plan as needed.

Starting Wegovy Maintenance Dose Treatment at Cured Pharmacy

Wegovy is available from Cured Pharmacy at £79.00, with all pricing displayed transparently before you begin your free online consultation. As a GPhC-registered pharmacy (registration number 9012511), we dispense only genuine UK-licensed semaglutide manufactured to MHRA standards.

Your clinical assessment takes under 3 minutes and is reviewed by UK-registered prescribers who evaluate your medical history, current medications, and weight management goals. If Wegovy is deemed clinically appropriate, we'll arrange discreet delivery directly to your address with 100% discreet packaging.

Treatment requires ongoing monitoring and prescription renewals as you progress through titration into the maintenance phase. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical services, ensuring every patient receives safe, evidence-based care throughout their weight loss journey. You can contact our team on (+44) 116 4646009 with any questions about maintenance dose treatment or eligibility criteria.

What to Expect from Your Consultation

The online assessment covers your BMI, weight-related health conditions, previous weight loss attempts, current medications, and any contraindications to semaglutide therapy. UK prescribers follow NICE guidance and MHRA licensing criteria when determining eligibility, ensuring treatment is both safe and appropriate for your individual circumstances.

If approved, your first prescription will begin with the 0.25mg starter dose, progressing through the titration schedule until you reach the 2.4mg maintenance dose after approximately 16 weeks. Ongoing prescriptions require periodic reassessment to monitor progress and ensure continued clinical benefit.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Garvey, W. T., Mechanick, J. I., Brett, E. M., et al. (2016). American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice, 22(Supplement 3), 1–203. https://doi.org/10.4158/EP161365.GL [accessed 13 August 2026]
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy (semaglutide) is a prescription-only medicine licensed by the MHRA for weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities, alongside reduced-calorie diet and increased physical activity.